文献速递胸部肿瘤

Telisotuzumab vedotin联合奥希替尼治疗c-Met蛋白过表达、EGFR突变且经奥希替尼进展后局部晚期/转移性非小细胞肺癌的Ib期研究结果

Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.
PubMed 文献 · Ann Oncol · 2025-01-11

这项多中心、开放标签的I/Ib期研究评估了Teliso-V联合奥希替尼在经奥希替尼进展后c-Met蛋白过表达、EGFR突变非鳞状非小细胞肺癌患者中的疗效与安全性。38例患者接受治疗,未观察到剂量限制性毒性,独立中心审查的客观缓解率为50.0%,中位无进展生存期为7.4个月,安全性可控。

要点

  • Teliso-V联合奥希替尼在经奥希替尼进展的c-Met过表达EGFR突变NSCLC中客观缓解率达50.0%。
  • 中位随访7.4个月,中位无进展生存期为7.4个月,缓解持续时间未达到。
  • 常见任何级别治疗中出现的不良事件为周围感觉神经病(50%)、外周水肿(32%)和恶心(24%)。

核心结论

  • Teliso-V联合奥希替尼在经奥希替尼进展后c-Met蛋白过表达、EGFR突变非鳞状非小细胞肺癌患者中显示出有前景的抗肿瘤活性和可控的安全性。
  • 该联合方案有潜力满足该患者群体未被满足的医疗需求。

研究设计与样本

  • 多中心、开放标签的I/Ib期研究(NCT02099058),纳入经奥希替尼进展后晚期EGFR突变、c-Met蛋白过表达、非鳞状非小细胞肺癌患者。
  • 患者接受Teliso-V静脉给药每2周一次联合奥希替尼口服80 mg每日一次;Teliso-V在安全性导入期评估1.6 mg/kg并递增至1.9 mg/kg,剂量扩展阶段包括两个剂量。
  • 共38例患者接受Teliso-V(1.6 mg/kg组20例;1.9 mg/kg组18例)联合奥希替尼并纳入分析。

主要发现

  • 未观察到剂量限制性毒性。
  • 最常见的任何级别治疗中出现的不良事件为周围感觉神经病(50%)、外周水肿(32%)和恶心(24%)。
  • 最常见的3/4级治疗中出现的不良事件为贫血(11%)和肺栓塞(8%)。
  • 5例治疗中出现的不良事件导致死亡,均未报告与Teliso-V或奥希替尼相关。
  • Teliso-V联合奥希替尼的药代动力学特征与Teliso-V单药相似。

关键数值与推荐

  • 中位随访7.4个月后,独立中心审查的客观缓解率为50.0%,缓解持续时间未达到。
  • 独立中心审查的中位无进展生存期为7.4个月(95%置信区间5.4个月至未达到)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression. In this article, we report the results of a phase I/Ib trial evaluating Teliso-V plus osimertinib in patients with NSCLC after progression on osimertinib. PATIENTS AND METHODS: This multicenter, open-label study (NCT02099058) enrolled patients with advanced EGFR-mutated, c-Met protein-overexpressing, non-squamous NSCLC that had progressed on prior osimertinib. Patients received Teliso-V (intravenously, every 2 weeks) plus osimertinib (orally, 80 mg once daily). Teliso-V was evaluated at 1.6 mg/kg in a safety lead-in phase and escalated to 1.9 mg/kg. Dose expansion included both doses. Endpoints included safety and tolerability, pharmacokinetics, objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS). RESULTS: A total of 38 patients received Teliso-V (1.6 mg/kg, n = 20; 1.9 mg/kg, n = 18) plus osimertinib and were included in this analysis. No dose-limiting toxicities were observed. Most frequent any-grade treatment-emergent adverse events (TEAEs) were peripheral sensory neuropathy (50%), peripheral edema (32%), and nausea (24%). Most common grade 3/4 TEAEs were anemia (11%) and pulmonary embolism (8%). Five TEAEs led to death; none were reported as being related to Teliso-V or osimertinib. The pharmacokinetic profile of Teliso-V plus osimertinib was similar to Teliso-V monotherapy. After a median follow-up of 7.4 months, the ORR was 50.0% per independent central review (ICR) (DOR not reached), and median PFS per ICR was 7.4 months (95% confidence interval 5.4 months-not reached). CONCLUSIONS: Teliso-V plus osimertinib had promising activity and a manageable safety profile in patients with c-Met protein-overexpressing, EGFR-mutated non-squamous NSCLC after progression on osimertinib. This combination has the potential to address an unmet medical need in this patient population.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Horinouchi H, Cho BC, Camidge DR, et al. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025. PMID: 39805351. doi:10.1016/j.annonc.2025.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。